Anavex Life Sciences Corp (AVXL)

[sokol]

Right. I believe it is inappropriate at this point for Anavex speak about a patient's decision to "switch" to mono-therapy. Anavex cannot / should not make any statements about a patient's choice. Such statements may also unduly stress other patients and and interfere with their physicians' decisions about treatment decisions. It may be comforting to you as an investor, but Anavex should not do that. It cannot say anything directly or indirectly that suggests AVXL 2-73, an unapproved drug, is superior to SOC.